| High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG). | |
| | |
MedLine Citation:
|
PMID: 16767936 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: Immunotherapy with Bacillus Calmette Guerin (BCG) has been widely used recently as primary option for treatment of high grade superficial (G3T1) carcinoma of the bladder. We describe our long term experience of therapy of G3T1 bladder cancer. METHODS: From January 1982 to December 2000, 785 patients were diagnosed with superficial bladder cancer. All patients underwent preoperative CT scan and transurethral resection of the bladder. Eighty-six patients (11%) had histological high grade superficial bladder cancer infiltrating the lamina propria. This group was treated with the following schedule of BCG Pasteur strain plus maintenance. Four cycles BCG, 6 instillations per cycle, first cycle weekly x 6, second cycle every 2 weeks x 6, third cycle monthly x 6, fourth cycle (maintenance) every 3 months x 6 instillations. RESULTS: The median follow-up is 91 months (30-197 months). The overall recurrence rate was 35% (30/86). The median time to recurrence was 29 months (5-128 months). Of these patients, 12 (14%) had progression at a median follow-up of 16 months (range 8-58 months). Cystectomy was needed in 8 (9%) patients. Death due to disease occurred in 5/86 (6%) patients. One patient died due to adenocarcinoma at the ureterosigmoidostomy site. Sixty-four (74%) patients are alive at a median follow-up of 71 months (range 28-197 months). Sixty patients (70%) are alive with an intact bladder. CONCLUSIONS: Treatment with BCG is a feasible conservative therapy for patients with primary G3T1 transitional bladder cancer. Long term results of BCG treatment are excellent. Cystectomy shouldn't be considered first line treatment for high grade superficial carcinoma of the bladder. |
| | |
Authors:
|
V Pansadoro; P Emiliozzi; F depaula; P Scarpone; M Pizzo; G Federico; M Martini; A Pansadoro; C N Sternberg |
Related Documents
:
|
3625846 - Bladder irrigation with chlorhexidine for the prevention of urinary infection after tra... 18060956 - A randomized, controlled trial evaluating 2 techniques of postoperative bladder testing... 11851766 - Prognosis of conservative therapy of advanced interstitial cystitis: experience of five... 20527606 - In women with urinary incontinence how necessary is cystometry? 16586386 - Use of real-time quantitative polymerase chain reaction to monitor the evolution of bru... 22882846 - Mortality and morbidity of acute hypoxemic respiratory failure and acute respiratory di... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of experimental & clinical cancer research : CR Volume: 22 ISSN: 0392-9078 ISO Abbreviation: J. Exp. Clin. Cancer Res. Publication Date: 2003 Dec |
Date Detail:
|
Created Date: 2006-06-13 Completed Date: 2006-08-09 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8308647 Medline TA: J Exp Clin Cancer Res Country: Italy |
Other Details:
|
Languages: eng Pagination: 223-7 Citation Subset: IM |
Affiliation:
|
Vincenzo Pansadoro Foundation and San Giovanni Hospital, Rome, Italy. paoloemiliozzi@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Intravesical Adult Aged Aged, 80 and over Carcinoma, Transitional Cell / mortality, therapy* Disease Progression Female Humans Immunotherapy* Male Middle Aged Mycobacterium bovis* / immunology Neoplasm Recurrence, Local / epidemiology Survival Rate Treatment Outcome Urinary Bladder Neoplasms / mortality, therapy* |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Soft tissue sarcomas: research of prognostic factors and therapeutics scheme.
Next Document: Epiadryamicin concentration in experimental hepatic metastases after bolus or continous infusion thr...